Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock

 
• By Cathy Kelly

Public statements by Novartis and AveXis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?

Sales problem business concept as a price tag pulling on a heavy anchor as a financial crisis metaphor and slow economy or sluggish retail selling symbol as a 3D illustration icon.

More from Pricing Debate

More from Market Access